Vivimed Labs gets DGHS nod to manufacture, market Favipiravir tablets in India

Vivimed Labs in receipt of Government of India (DGHS) approval to manufacture and market Favipiravir tablets in the strengths of 200 mg and 400 mg under Vivimed’s own brand name ‘Favulous’ across India, the company said in a regulatory filing.

PTI
May 10, 2021 / 12:57 PM IST
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Drug firm Vivimed Labs on Monday said it has received approval from the Director General of Health Services (DGHS) to manufacture and market Favipiravir tablets in India, used for the treatment of mild to moderate cases of COVID-19.

Vivimed Labs in receipt of Government of India (DGHS) approval to manufacture and market Favipiravir tablets in the strengths of 200 mg and 400 mg under Vivimed’s own brand name ‘Favulous’ across India, the company said in a regulatory filing.

It is used for the treatment of mild to moderate cases of COVID-19. Favipiravir is one of the leading oral anti-viral treatment approved in various countries for the potential treatment of patients with mild to moderate COVID-19 disease.

Ramesh Krishnamurthy, CEO of Vivimed Labs said, “With huge spike in COVID-19 cases being reported daily in India, there is an urgent need to provide more treatment options to healthcare professionals.”

“We are launching Favulous at a competitive price to make the drug accessible to more and more patients thereby ensuring good health and reducing their financial burden. This is in line with Vivimed’s commitment to be at forefront in India’s fight against COVID-19.”

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show
The company said it will work closely with the various governments and medical community to ensure availability of Favulous to patients across the country.
PTI
TAGS: #Business #Companies #coronavirus #Covid-19 #Favipiravir #Vivimed Labs
first published: May 10, 2021 12:57 pm